These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4911257)

  • 21. Levodopa.
    Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
    [No Abstract]   [Full Text] [Related]  

  • 22. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 23. L-Dopa in the treatment of parkinsonism.
    Calne DB
    Clin Pharmacol Ther; 1970; 11(6):789-801. PubMed ID: 4921292
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 25. The influence of L-dopa on physical treatment of Parkinsonism.
    Mikkelsen B; Dupont E; Worm-Petersen J
    Acta Neurol Scand Suppl; 1972; 51():127-8. PubMed ID: 4576069
    [No Abstract]   [Full Text] [Related]  

  • 26. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 27. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 28. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 29. Slowly absorbed L-dopa preparation in the treatment of parkinsonism.
    Laitinen LV
    Acta Neurol Scand; 1973; 49(3):331-8. PubMed ID: 4747020
    [No Abstract]   [Full Text] [Related]  

  • 30. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 31. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of severe parkinsonism with L-dopa.
    Reef HE; Joffe R; Milletz H
    S Afr Med J; 1971 May; 45(18):504-7. PubMed ID: 4941208
    [No Abstract]   [Full Text] [Related]  

  • 33. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 35. Levodopa in Parkinsonism.
    Weiss JL; Chase TN
    Drugs; 1971; 2(4):257-61. PubMed ID: 4948349
    [No Abstract]   [Full Text] [Related]  

  • 36. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 37. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 39. Theoretical implications of the use of L-dopa in parkinsonism. A review.
    Klawans H; Ilahi MM; Shenker D
    Acta Neurol Scand; 1970; 46(4):409-41. PubMed ID: 4323341
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa in idiopathic parkinsonism.
    Calne DB; Stern GM; Spiers AS; Laurence DR
    Lancet; 1969 Nov; 2(7628):973-6. PubMed ID: 4186975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.